Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

oss for the year ended December 31, 2012 was $15.6 million, or $0.33 per share (basic and diluted), compared to a net loss of $13.3 million, or $0.47 per share (basic and diluted), for the same period in 2011.

R&D expenses for the year ended December 31, 2012 were $8.1 million, an increase of $2.3 million, or 41%, compared to $5.8 million for the same period in 2011. The increase was due to a $1.2 million increase in personnel costs, a $0.6 million increase in external clinical study fees and expenses and a $0.5 million increase in external nonclinical study fees. The increase in personnel costs was primarily related to additional clinical and research-related manufacturing staff hired in 2012, including relocation and recruitment costs for our new Chief Medical Officer. The increase in external clinical study fees and expenses was related primarily to a $0.8 million increase in clinical consulting and phase 3 study planning expenses for MST-188, offset by a $0.2 million decrease in clinical consulting expenses for ANX-514 and ExelbineTM.  The increase in external nonclinical study fees and expenses was related primarily to a $2.0 million increase in research-related manufacturing activities and regulatory affairs-related consulting expenses for MST-188 and a $0.7 million increase in research-related manufacturing activities for ANX-514, offset by a $2.2 million decrease in commercial-readiness manufacturing activities for Exelbine.  Due to its focus on MST-188, the Company elected to discontinue independent development of its ANX-514 and Exelbine programs in 2012 and 2011, respectively.

SG&A expenses for the year ended December 31, 2012 were $7.5 million, an increase of $0.3 million, or 5%, compared to $7.2 million for the same period in 2011. The net increase resulted from a $0.7 million increase in personnel costs, mainly due to additional staff hired in 2012, and a $0.5 million increase in share-based compensation expe
'/>"/>

SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... ALEXANDRIA, Va., Sept. 1 The ... of a new website, www.PharmacyMatching.com to ... their pharmacy, existing owners who desire additional stores ... become a pharmacy owner. (Logo: ...
... Sept. 1 Eli Lilly and Company (NYSE: ... for the Federal Circuit has affirmed a prior ruling by ... that the company,s method-of-use patents for Evista® (raloxifene HCl tablets) ... U.S. through March of 2014. "We are pleased ...
Cached Medicine Technology:NCPA Launches www.PharmacyMatching.com to Connect Independent Pharmacy Buyers and Sellers 2NCPA Launches www.PharmacyMatching.com to Connect Independent Pharmacy Buyers and Sellers 3U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014 2
(Date:7/14/2014)... The Encino cosmetic dentist at ... and porcelain veneers. These restorations are an excellent ... and greater loss of healthy tooth tissue. They work ... flaws on the tooth. Encino dentist Dr. Mastour and ... ensure they offer the most appropriate treatment recommendations for ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... based on computerized simulation models suggests that the lifetime risk ... tomography (CT scan) coronary angiography varies widely, with the risk ... disease (CAD) is the leading cause of death in men ... 5 deaths, and a major cause of health care expenditures, ...
... reveals abnormal cells the woman will be offered colposcopy, ... cervix with a special microscope. Many women find the ... of anxiety before and during colposcopy. ,,Researchers ... trials that involved a total of 1441 women and ...
... The U.S. Food and Drug Administration (FDA) has approved the ... degenerative disc disease , one of the most common causes ... approved, the Prestige Cervical Disc, is manufactured by Medtronic Sofamor ... disc means that people with cervical degenerative disc disease now ...
... law to curb smoking to secure peoples' rights to the ... much committed towards implementing a comprehensive anti-tobacco law to reduce ... children and adolescents," Ali bin Shukur, Under-secretary of the Ministry ... ,A draft bill on smoking is being deliberated at ...
... of researchers have found that combining pre-operative chemotherapy and ... six percent when compared with surgery alone. ... the MRC Clinical Trials Unit in London after they ... from seven of these trials were available from trial ...
... a plan for coping with a pandemic flu outbreak, the ... disease outbreak and track its progress across the country. ... the borders if a pandemic flu outbreak occurs somewhere in ... president for biodefense:The reality is that there are tremendous challenges ...
Cached Medicine News:Health News:CT Scan Radiations may Lead to Cancer 2Health News:FDA Approves First Artificial Cervical Disc 2Health News:Chemotherapy Better for Non Small Cell Lung cancer 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... quantitative determination of Estradiol (E2) concentration in human ... steroid hormone with a phenolic A ring. ... 272.4. It is the most potent natural ... in smaller amounts by the adrenal cortex, and ...
... Cardiac troponin I (cTnI) has been ... presenting to Emergency Departments (ED) with chest ... is diagnosed when blood levels of sensitive ... the MB isoenzyme of creatine kinase (CK-MB), ...
Medicine Products: